Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
-
Clinical Benefit
Substantial
The actual benefit provided by TEGELINE in this indication is substantial.
Clinical Added Value
important
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy.
Listen
